À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÔÚ2023 ESMO´ó»áÉÏչʾÖ×Áö²úÎïÏߺÍÏà¹ØÑо¿½øÕ¹Çé¿ö

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉçÐû²¼£¬½«ÔÚ10ÔÂ20ÈÕÖÁ24ÈÕÓÚÎ÷°àÑÀÂíµÂÀï¾ÙÐеÄÅ·ÖÞÖ×ÁöÄÚ¿Æѧ»á£¨ESMO£©2023 Äê´ó»áÆڼ䣬½éÉÜÆäÖ×Áö²úÎïÏߺÍÏà¹ØÑо¿½øÕ¹Çé¿ö¡£

¾«²ÊÄÚÈÝ°üÂÞ£ºÒªº¦ÐÔIIIÆÚCLEAR£¨Ñо¿307£©/KEYNOTE-581ÊÔÑéתÒƵĻùÏßÌØÕ÷¶ÔÖ×Áö·´Ó³½øÐеÄʺó·ÖÎö£¬¸ÃÊÔÑéÆÀ¹ÀÁËÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ñз¢µÄ¿Ú·þ¶à°ÐµãÀÒ°±ËἤøÊÜÌåÒÖÖƼÁÀÖÎÀÂê?£¨ÂØ·¥ÌæÄᣩÁªºÏMSDµÄ¿¹PD-1ÁÆ·¨¿ÉÈð´ï?£¨ÅÁ²©ÀûÖéµ¥¿¹£©ÓëÊæÄáÌæÄáÓÃÓÚÍíÆÚÉöϸ°û°©»¼ÕßÒ»ÏßÖÎÁƵÄÇé¿ö£¨NCT02811861£»ÑÝʾÎĸ壺#1903P£©¡£´ËÍ⣬»¹½«½éÉÜÒªº¦ÐÔ IIIÆÚÑо¿ 309/KEYNOTE-775 ÊÔÑé¶ÔÍê³ÉÅÁ²©ÀûÖéµ¥¿¹ÖÎÁƲ¢¼ÌÐø½ÓÊÜÂØ·¥ÌæÄáÖÎÁƵÄÍíÆÚ×Ó¹¬ÄÚĤ°©»¼ÕßµÄÁÆЧ½øÐеÄ̽Ë÷ÐÔ·ÖÎö£¨NCT03517449£»Ñݽ²£º#748P£©¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ê×ϯ¿Æѧ¹Ù¼æ¸ß¼¶¸±×ܲÃTakashi Owa²©Ê¿ÌåÏÖ£¬¡°×÷Ϊһ¼ÒÒÔ¡±hhc¡±£¨human health care, ÌåÌùÈËÀཡ¿µ£©ÀíÄîΪÇý¶¯Á¦µÄÑз¢Ð͹«Ë¾£¬ÎÒÃÇÖÂÁ¦ÓÚͨ¹ýÎÒÃÇÇ¿´óµÄ²úÎï×éºÏºÍ¹ÜÏßÀ´Íƶ¯°©Ö¢Ò©Îï¿ÆѧµÄÉú³¤£¬´Ó¶ø¸ÄÉÆ»¼Õß¼°Æä¼ÒÊôµÄÉú»î¡£ÔÚ½ñÄêµÄESMO»áÒéÉÏ£¬À´×ÔÒªº¦ÐÔIIIÆÚCLEARÊÔÑéºÍ309/KEYNOTE-775ÊÔÑéµÄ·ÖÎö½á¹û£¬¿ÉÄÜ»áΪÍíÆÚÉöϸ°û°©ºÍijЩÀàÐ͵ÄÍíÆÚ×Ó¹¬ÄÚĤ°©»¼ÕßµÄÖÎÁÆÌṩ¸üÉîÈëµÄÁ˽â¡£ÎÒÃÇÒ²ÆÚ´ý×Å·ÖÏíÂØ·¥ÌæÄáºÍÑз¢Êý¾Ý£¬²¢ÓëÉç»á¸÷½ç½øÐÐÖØÒªµÄ¿Æѧ½»Á÷£¬ÅäºÏÍƶ¯Ö×ÁöÑо¿ÏòÇ°Éú³¤¡£¡±

LEAP (LEnvatinib And Pembrolizumab)ÁÙ´²ÏîÄ¿½«Ðû²¼ÆäËüÊý¾Ý£¬°üÂÞLEAP-014ÈýÆÚÊÔÑéµÄÄþ¾²ÐÔÊÔÑé½á¹û£¬¸ÃÊÔÑéÆÀ¹ÀÁËÂØ·¥ÌæÄáÁªºÏÅÁ²©ÀûÖéµ¥¿¹ºÍ»¯ÁÆ×÷Ϊʳ¹ÜÁÛ°©»¼ÕßµÄÖÎÁÆ·½°¸Ñ¡ÏNCT04949256£»Ñݽ²£º#1534P£©¡£ÂØ·¥ÌæÄáÓëÖ÷Òª¶Ô±ÈÒ©Îï×÷Ϊ²»ÐÐÇгý¸Îϸ°û°©»¼ÕßÒ»ÏßÖÎÁÆ·½°¸µÄÍøÂçÜöÝÍ·ÖÎöÒ²½«ÔÚ»áÒ麣±¨ÉÏչʾ£¨Ñݽ²£º#1007P£©¡£

ÆäËüÑо¿½á¹ûÒ²½«ÔÚº£±¨ÉÏչʾ£¬È磺ÆÀ¹À°¬Á¢²¼ÁÖµÄÖ¬ÖÊÌåÖƼÁE7389-LF×÷ΪתÒÆÐÔ/ÍíÆÚHER2ÒõÐÔÈéÏÙ°©»¼ÕßDZÔÚÒ»Ïß»¯ÁÆÑ¡ÔñµÄIÆÚÑо¿¼ÁÁ¿À©Õ¹²¿ÃŵĽá¹û£¨Ñݽ²£º#405P£©¡£´ËÍ⣬»¹½«½éÉÜfarletuzumab ecteribulin£¨FZEC£¬Ô­ÃûMORAb-202£©µÄÁÙ´²Ç°Ñо¿·ÖÏí£¬ÕâÊÇÒ»ÖÖÒ¶ËáÊÜÌå¦Á£¨FR¦Á£©°ÐÏò¿¹Ìå-Ò©ÎïżÁªÎADC£©£¬ÓÃÓÚ×Ó¹¬ÄÚĤ°©Ö¢£¨Õ¹Ê¾£º#786P£©¡£

±¾ÐÂΟåÌÖÂÛÁËÑо¿ÐÔ»¯ºÏÎïºÍFDAÒÑÅú×¼²úÎïµÄÑо¿ÐÔÓÃ;¡£²¢·Çת´ï¹ØÓÚÁÆЧºÍÄþ¾²ÐԵĽáÂÛ£¬²»±£Ö¤ÈκÎÑо¿ÐÔ»¯ºÏÎï»òFDAÒÑÅú×¼²úÎïµÄÑо¿ÐÔÓÃ;½«ÀÖ³ÉÍê³ÉÁÙ´²¿ª·¢»ò»ñµÃFDAÅú×¼¡£

ÍêÕûÇåµ¥ÈçÏ£¬ÕâЩժҪ½«ÓÚ½«ÓÚ2023Äê10ÔÂ16ÈÕÐÇÆÚÒ»ÉÏÎç12:05ͨ¹ýESMOÍøÕ¾Ìṩ¡£

ÀûÀ´w66(ÖйúÇø)_À´Àû¹ú¼ÊÆì½¢

?

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120